SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Filing Date
Apr 28, 2021
Document Date
Apr 28, 2021
Form Description
Additional proxy soliciting materials - definitive
Filing Group
Proxy Filings
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.